Latest Health Technology at CES 2021
MPR highlights health innovations from the 2021 Consumer Electronics Show (CES).
Allergies
Ligelizumab Gets Breakthrough Tx Status for Chronic Spontaneous Urticaria
Ligelizumab is a high-affinity monoclonal anti-immunoglobulin E (IgE) antibody.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
FDA Approves Orladeyo to Prevent Hereditary Angioedema Attacks
Orladeyo works by binding to plasma kallikrein and inhibiting its proteolytic activity.
Exhalation Delivery System vs Intranasal Spray for Nasal Polyp Treatment
An exhalation delivery system appears to more effectively apply topical steroids to nasal polyps located in the ostiomeatal complex.
Crisaborole Safe, Efficacious in Atopic Dermatitis, With or Without Allergic Rhinitis
The safety and efficacy of crisaborole ointment, 2%, was examined in pediatric patients with mild to moderate atopic dermatitis with and without comorbid allergic rhinitis.
Flare Size in Skin Prick Test May Predict Oral Food Challenge Outcomes
Larger skin flare results in pediatric patients correlated to failing certain oral food challenges, but were not predictive of requiring epinephrine.
Omalizumab Shows Continued Efficacy for Chronic Rhinosinusitis With Nasal Polyps
Treatment with omalizumab for up to 1 year was associated with continued improvements in symptoms of chronic rhinosinusitis with nasal polyps.
Lanadelumab Markedly Reduces Hereditary Angioedema Attacks Over 30-Month Period
Lanadelumab was effective for reducing hereditary angioedema attacks at up to 30 weeks of treatment, suggesting the monoclonal antibody is associated with sustained long-term efficacy.
Berotralstat Improves Quality of Life in Hereditary Angioedema
Patients with hereditary angioedema taking berotralstat prophylactically had improved quality of life.
